导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.06% | 2834/4773 |
| 近一周 | -1.63% | 607/5462 |
| 近一月 | 1.20% | 409/5421 |
| 近一季 | 1.19% | 572/5209 |
| 近半年 | -3.33% | 2177/4920 |
| 近一年 | 1.66% | 2292/4366 |
| 近两年 | 37.75% | 1985/2954 |
| 近三年 | 36.31% | 822/2253 |
| 成立以来 | 140.37% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.34% 3147/4961 |
-5.89% 3635/5312 |
- - |
- - |
| 2025 | 18.43% 2318/4813 |
-0.14% 2079/3635 |
4.68% 714/4076 |
9.57% 3345/4524 |
3.40% 682/4813 |
| 2024 | 23.94% 314/3463 |
9.92% 100/2808 |
1.64% 460/3014 |
13.76% 2111/3129 |
-2.49% 2107/3463 |
| 2023 | -0.91% 478/2656 |
3.07% 1271/2280 |
0.62% 299/2385 |
0.73% 347/2515 |
-5.15% 1271/2655 |
| 2022 | -10.46% 206/2207 |
-5.77% 205/1919 |
1.67% 1442/2016 |
-8.37% 195/2113 |
2.00% 1065/2208 |
| 2021 | 11.64% 399/1822 |
2.98% 202/1255 |
0.58% 1092/1330 |
6.35% 229/1466 |
1.35% 957/1822 |
| 2020 | 27.34% 585/1250 |
-8.64% 625/1028 |
11.35% 737/1067 |
15.52% 210/1164 |
8.35% 678/1184 |
| 2019 | 37.41% 334/1092 |
23.20% 562/754 |
2.08% 100/804 |
1.48% 397/850 |
7.67% 411/918 |
| 2018 | - - |
- - |
- - |
- - |
-12.07% 397/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中金优选300指数(LOF)C VS. 长安沪深300非周期A(740101) |